FingerMotion, Inc. Common Stock

Go to FingerMotion, Inc. Common Stock Website

$1.52

0.00 (0.00%)
Live
Previous Close

$1.52

Day Range

$0 - $0

Previous Day Range

$1.5 - $1.57

Market Cap

$91.5 million USD

Day Vol.

0

Previous Day Vol.

179638

Currency

USD

Primary Exchange

Nasdaq

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) a...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. IHS Holding Limited (NYSE: IHS) On Jan. 16, IHS Towers and Wendel Group agreed on corporate governance matters. Sam Darwish, IHS Towers Chairman and CEO commented: "We believe the agreement announced today better aligns IHS Towers’ corporate governance with that of mature U.S.-listed companies, which was an important goal ...

Related tickers: IHS, AMC, IQ, FNGR.

Read Full Article

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session. Li-Cycle Holdings Corp. (NYSE: LICY) shares dipped 41% to $1.34 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project. Revolution Medicines, Inc. (NASDAQ: RVMD) fell 38% to $17.31 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236. Ambrx Biopharma Inc. (NASDAQ: AMAM) declined 22% to $6.58. Ambrx announced ...

Related tickers: FORTY, PERF, WRLD, FMC, YPF, OKTA, FNGR, RVMD, AMAM, LICY, NAMS, VFS.

Read Full Article
Trending Tickers

Please sign in to view